Research theme for competitive and other funds (4)：
2022 - 2025 PAI-1・免疫チェックポイント相互阻害による新規免疫療法の開発
2020 - 2022 LL37 might promote local invasion of melanoma by the stimulation of melanoma cells and tumor-associated macrophages
2016 - 2019 Development of novel immune therapy for melanoma by targeting tumor associated macrophages
2016 - 2018 Possible mechanisms of induction of immunotolerance in appocrine-origin skin tumors
Papers (134)：
Yusuke Muto, Yumi Kambayashi, Hiroshi Kato, Satoshi Fukushima, Takamichi Ito, Takeo Maekawa, Yasuhiro Fujisawa, Koji Yoshino, Hiroshi Uchi, Shigeto Matsushita, et al. Adverse events associated with postoperative outcomes of adjuvant anti-PD-1 antibody therapy in both acral and non-acral cutaneous melanomas: A multicenter, observational, post hoc analysis study. The Journal of dermatology. 2023
Yusuke Muto, Yumi Kambayashi, Hiroshi Kato, Satoshi Fukushima, Takamichi Ito, Takeo Maekawa, Ishizuki Shoichiro, Hiroshi Uchi, Shigeto Matsushita, Yuki Yamamoto, et al. Postoperative adjuvant therapy for120 melanoma patients, including acral and mucosal subtypes: A multicenter, observational study of two-year follow-up results. The British journal of dermatology. 2023
Taku Fujimura, Takeo Maekawa, Hiroshi Kato, Takamichi Ito, Shigeto Matsushita, Koji Yoshino, Yasuhiro Fujisawa, Shoichiro Ishizuki, Kojiro Segawa, Jun Yamamoto, et al. Treatment for taxane-resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases. The Journal of dermatology. 2023
Yusuke Muto, Yumi Kambayashi, Hiroshi Kato, Satoshi Fukushima, Takamichi Ito, Takeo Maekawa, Yasuhiro Fujisawa, Koji Yoshino, Hiroshi Uchi, Shigeto Matsushita, et al. Adjuvant Anti-PD-1 Antibody Therapy for Advanced Melanoma: A Multicentre Study of 78 Japanese Cases. Acta dermato-venereologica. 2022. 102. adv00756
